149 related articles for article (PubMed ID: 27740765)
1. Systemically Administered RNAi Molecule Sensitizes Malignant Pleural Mesotheliomal Cells to Pemetrexed Therapy.
Abu Lila AS; Fukushima M; Huang CL; Wada H; Ishida T
Mol Pharm; 2016 Nov; 13(11):3955-3963. PubMed ID: 27740765
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model.
Abu Lila AS; Kato C; Fukushima M; Huang CL; Wada H; Ishida T
Int J Oncol; 2016 Apr; 48(4):1399-407. PubMed ID: 26847426
[TBL] [Abstract][Full Text] [Related]
3. Encapsulation in a rapid-release liposomal formulation enhances the anti-tumor efficacy of pemetrexed in a murine solid mesothelioma-xenograft model.
Eldin NE; Abu Lila AS; Kawazoe K; Elnahas HM; Mahdy MA; Ishida T
Eur J Pharm Sci; 2016 Jan; 81():60-6. PubMed ID: 26415830
[TBL] [Abstract][Full Text] [Related]
4. Co-administration of liposomal l-OHP and PEGylated TS shRNA-lipoplex: A novel approach to enhance anti-tumor efficacy and reduce the immunogenic response to RNAi molecules.
Alaaeldin E; Abu Lila AS; Ando H; Fukushima M; Huang CL; Wada H; Sarhan HA; Khaled KA; Ishida T
J Control Release; 2017 Jun; 255():210-217. PubMed ID: 28461099
[TBL] [Abstract][Full Text] [Related]
5. Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed.
Ando H; Kobayashi S; Abu Lila AS; Eldin NE; Kato C; Shimizu T; Ukawa M; Kawazoe K; Ishida T
J Control Release; 2015 Dec; 220(Pt A):29-36. PubMed ID: 26476173
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed-conjugated hyaluronan for the treatment of malignant pleural mesothelioma.
Amano Y; Ohta S; Sakura KL; Ito T
Eur J Pharm Sci; 2019 Oct; 138():105008. PubMed ID: 31302213
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.
Monica V; Lo Iacono M; Bracco E; Busso S; Di Blasio L; Primo L; Peracino B; Papotti M; Scagliotti G
Oncotarget; 2016 Nov; 7(47):76577-76589. PubMed ID: 27391433
[TBL] [Abstract][Full Text] [Related]
8. Liposomal pemetrexed: formulation, characterization and in vitro cytotoxicity studies for effective management of malignant pleural mesothelioma.
Essam Eldin N; Elnahas HM; Mahdy MA; Ishida T
Biol Pharm Bull; 2015; 38(3):461-9. PubMed ID: 25757929
[TBL] [Abstract][Full Text] [Related]
9. Metronomic S-1 dosing and thymidylate synthase silencing have synergistic antitumor efficacy in a colorectal cancer xenograft model.
Abu Lila AS; Moriyoshi N; Fukushima M; Huang CL; Wada H; Ishida T
Cancer Lett; 2017 Aug; 400():223-231. PubMed ID: 27838412
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
[TBL] [Abstract][Full Text] [Related]
11. Combination effect of photodynamic therapy using NPe6 with pemetrexed for human malignant pleural mesothelioma cells.
Maehara S; Usuda J; Ishizumi T; Ichinose S; Ohtani K; Inoue T; Imai K; Furumoto H; Kudo Y; Kajiwara N; Ohira T; Ikeda N
Int J Oncol; 2015 Feb; 46(2):741-9. PubMed ID: 25385189
[TBL] [Abstract][Full Text] [Related]
12. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
Zucali PA; Giovannetti E; Destro A; Mencoboni M; Ceresoli GL; Gianoncelli L; Lorenzi E; De Vincenzo F; Simonelli M; Perrino M; Bruzzone A; Thunnissen E; Tunesi G; Giordano L; Roncalli M; Peters GJ; Santoro A
Clin Cancer Res; 2011 Apr; 17(8):2581-90. PubMed ID: 21262916
[TBL] [Abstract][Full Text] [Related]
13. A simplified method for manufacturing RNAi therapeutics for local administration.
Ando H; Abu Lila AS; Fukushima M; Matsuoka R; Shimizu T; Okuhira K; Ishima Y; Huang CL; Wada H; Ishida T
Int J Pharm; 2019 Jun; 564():256-262. PubMed ID: 31015002
[TBL] [Abstract][Full Text] [Related]
14. Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.
Mairinger F; Vollbrecht C; Halbwedl I; Hatz M; Stacher E; Gülly C; Quehenberger F; Stephan-Falkenau S; Kollmeier J; Roth A; Mairinger T; Popper H
J Thorac Oncol; 2013 May; 8(5):644-53. PubMed ID: 23449276
[TBL] [Abstract][Full Text] [Related]
15. Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.
Mairinger FD; Vollbrecht C; Flom E; Christoph DC; Schmid KW; Kollmeier J; Popper HH; Mairinger T; Walter RFH
Oncotarget; 2017 Jun; 8(23):37502-37510. PubMed ID: 28415584
[TBL] [Abstract][Full Text] [Related]
16. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
Powrózek T; Kowalski DM; Krawczyk P; Ramlau R; Kucharczyk T; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Dyszkiewicz W; Krzakowski M; Milanowski J
Clin Lung Cancer; 2014 Nov; 15(6):455-65. PubMed ID: 25246386
[TBL] [Abstract][Full Text] [Related]
17. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
Iwahori K; Serada S; Fujimoto M; Ripley B; Nomura S; Mizuguchi H; Shimada K; Takahashi T; Kawase I; Kishimoto T; Naka T
Int J Cancer; 2013 Jan; 132(2):459-71. PubMed ID: 22532243
[TBL] [Abstract][Full Text] [Related]
18. Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model.
Iizuka K; Jin C; Eshima K; Hong MH; Eshima K; Fukushima M
Drug Des Devel Ther; 2018; 12():673-683. PubMed ID: 29636601
[TBL] [Abstract][Full Text] [Related]
19. Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.
Lam SK; Li YY; Xu S; Leung LL; U KP; Zheng YF; Cheng PN; Ho JC
Respir Res; 2017 May; 18(1):80. PubMed ID: 28464918
[TBL] [Abstract][Full Text] [Related]
20. Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target.
Huang J; Tabata S; Kakiuchi S; The Van T; Goto H; Hanibuchi M; Nishioka Y
Oncotarget; 2013 Aug; 4(8):1172-84. PubMed ID: 23896451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
